Q901 for Cancer, Advanced

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Mary Crowley Cancer Research, Dallas, TX
Cancer, Advanced+2 More
Q901 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901

Eligible Conditions

  • Cancer, Advanced
  • Metastatic Cancers

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Cancer, Advanced

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Cycle 1 Day 1 and Day 22, Cycle 2 Day 8 and Day 22 (each cycle is 28 days)

Day 28
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Year 2
Tumor response using RECIST version 1.1 throughout study
Day 28
Change in the area under curve (AUC) of Q901
Change in the maximum plasma concentration (Cmax) of Q901
Change in the time of maximum plasma concentration (Tmax) of Q901

Trial Safety

Safety Progress

1 of 3

Other trials for Cancer, Advanced

Trial Design

1 Treatment Group

Dose escalation (Q901)
1 of 1
Experimental Treatment

70 Total Participants · 1 Treatment Group

Primary Treatment: Q901 · No Placebo Group · Phase 1 & 2

Dose escalation (Q901)
Drug
Experimental Group · 1 Intervention: Q901 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: cycle 1 day 1 and day 22, cycle 2 day 8 and day 22 (each cycle is 28 days)
Closest Location: Mary Crowley Cancer Research · Dallas, TX
Photo of Dallas 1Photo of Dallas 2Photo of Dallas 3
2021First Recorded Clinical Trial
8 TrialsResearching Cancer, Advanced
19 CompletedClinical Trials

Who is running the clinical trial?

Qurient Co., Ltd.Lead Sponsor
8 Previous Clinical Trials
677 Total Patients Enrolled
1 Trials studying Cancer, Advanced
78 Patients Enrolled for Cancer, Advanced

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.